The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

Documenti analoghi

• Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
  di: Amir Razaghizad, et al.
  Pubblicazione: (2024)
• Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
  di: Jan Oscarsson, et al.
  Pubblicazione: (2026)
• Waist‐to‐Height Ratio and the Risk of Cardiovascular Outcomes and Mortality in Type 2 Diabetes With and Without Abdominal Obesity
  di: Kye‐Yeung Park, et al.
  Pubblicazione: (2026)
• Effect of Caloric Restriction on Predicted Risk of Incident Cardiovascular Disease and Type 2 Diabetes in Young Adults: Findings From the CALERIE 2 Trial
  di: Ryan Chang, et al.
  Pubblicazione: (2026)
• Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model
  di: Lee‐Ling Lim, et al.
  Pubblicazione: (2026)